

## ACO Name and Location

Einstein Care Partners, LLC  
3300 Henry Avenue Falls 2 Suite 601  
Philadelphia PA 19129-1121

## ACO Primary Contact

Shivanandh Chandrasekaran, MD  
chandras@einstein.edu

## Organizational Information

### ACO Participants:

ACO Participants	ACO Participant in Joint Venture
Fornance Physician Services Inc	N
Einstein Practice Plan Inc	N
Einstein Community Health Associates, Inc	N

### ACO Governing Body:

Member Last Name	Member First Name	Member Title/Position	Member's Voting Power (Expressed as a percentage or number)	Membership Type	ACO Participant Legal Business Name and D/B/A, if applicable
Nicholas, MD	Angela	Co-Chair	1	ACO Participant Representative	Fornance Physician Services
Sivak, MD	Steven	Co-Chair	1	ACO Participant Representative	Einstein Practice Plan
Behme, MD	Matthew	Member	1	ACO Participant Representative	Einstein Practice Plan
Datner, MD	Elizabeth	Member	1	ACO Participant Representative	Einstein Practice Plan
Dubois	Ruth	Member	1	Medicare Beneficiary Representative	
Duffy	Beth	Member	1	ACO Participant Representative	Fornance Physician Services
Gulati, MD	Rohit	Member	1	ACO Participant Representative	Einstein Practice Plan
James	Dixie	Member	1	Other	Albert Einstein Medical Center
Johnson, MD	Ahashta	Member	1	ACO Participant Representative	Fornance Physician Services
Leighton, MD	John	Member	1	ACO Participant Representative	Einstein Practice Plan
Levitan	Ken	Member	1	Other	Einstein Healthcare Network
Rose, MD	Gina	Member	1	ACO Participant Representative	Fornance Physician Services
Scaven, MD	Christopher	Member	1	ACO Participant Representative	Einstein Community Health Associates
Chandrasekaran,	Shivanandh	Member	0	Other	Einstein Care

MD					Partners, LLC
----	--	--	--	--	---------------

**Key ACO Clinical and Administrative Leadership:**

ACO Executive: Shivanandh Chandrasekaran, MD  
 Medical Director: Shivanandh Chandrasekaran, MD  
 Compliance Officer: Marianne DeJesus  
 Quality Assurance/Improvement Officer: Shivanandh Chandrasekaran, MD

**Associated Committees and Committee Leadership:**

Committee Name	Committee Leader Name and Position
Clinical Performance and Integration Committee	Jason Aronovitz, DO (Co-Chair) and Shivanandh Chandrasekaran, MD (Co-Chair)
Membership and Nominating Committee	Angela Nicholas, MD (Co-Chair) and Steven Sivak, MD (Co-Chair)

**Types of ACO Participants, or Combinations of Participants, That Formed the ACO:**

- ACO professionals in a group practice arrangement
- Networks of individual practices of ACO professionals

**Shared Savings and Losses**

**Amount of Shared Savings/Losses:**

- Third Agreement Period
  - Performance Year 2020      \$6,273,203
- Second Agreement Period
  - Performance Year 2019      \$0
- First Agreement Period
  - Performance Year 2018      \$1,905,474

**Shared Savings Distribution:**

- Third Agreement Period
  - Performance Year 2020
    - Proportion invested in infrastructure: 10%
    - Proportion invested in redesigned care processes/resources: 10%
    - Proportion of distribution to ACO participants: 80%
- Second Agreement Period
  - Performance Year 2019
    - Proportion invested in infrastructure: N/A
    - Proportion invested in redesigned care processes/resources: N/A
    - Proportion of distribution to ACO participants: N/A
- First Agreement Period
  - Performance Year 2019
    - Proportion invested in infrastructure: 10%
    - Proportion invested in redesigned care processes/resources: 10%
    - Proportion of distribution to ACO participants: 80%

## Quality Performance Results

### 2020 Quality Performance Results:

ACO Quality Measure Number	Measure Name	Rate	ACO Mean
ACO-43	Ambulatory Sensitive Condition Acute Composite (AHRQ Prevention Quality Indicator (PQI #91))	0.79	0.95
ACO-13	Falls: Screening for Future Fall Risk	86.27	84.97
ACO-14	Preventative Care and Screening: Influenza Immunization	60.30	76.03
ACO-17	Preventative Care and Screening: Tobacco Use: Screening and Cessation Intervention	79.10	81.67
ACO-18	Preventative Care and Screening: Screening for Depression and Follow-up Plan	74.37	71.46
ACO-19	Colorectal Cancer Screening	61.46	72.59
ACO-20	Breast Cancer Screening	66.94	74.05
ACO-42	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	87.70	83.37
ACO-27	Diabetes Mellitus: Hemoglobin A1c Poor Control	18.86	14.70
ACO-28	Hypertension (HTN): Controlling High Blood Pressure	63.01	72.87

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low sample size. The Centers for Medicare & Medicaid Services (CMS) also waived the requirement for ACOs to field a CAHPS for ACOs survey for PY 2020 through the Physician Fee Schedule Final Rule for Calendar Year 2021. Additionally, CMS reverted ACO-8 Risk-Standardized, All

Condition Readmission and ACO-38 Risk-Standardized Acute Admission Rates for Patients with Multiple Chronic Conditions to pay-for-reporting, given the impact of the coronavirus disease 2019 (COVID-19) public health emergency (PHE) on these measures.

For Previous Years' Financial and Quality Performance Results, Please Visit [data.cms.gov](https://data.cms.gov)

- **ACO Participation Waiver:**

The following information describes each arrangement for which our ACO seeks protection under the ACO Participation Waiver, including any material amendment or modification to a disclosed arrangement.

- *Parties to the arrangement:* ACO and ACO Participants listed above
- *Date of arrangement:* January 1, 2018
- *Items, services, goods, or facility provided:* ACO provides administrative and analytic support to ACO Participants.
- *Date and nature of any amendments to the arrangement, if applicable:* N/A